Answers are grounded in this paper and cite their sources.
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuronal loss and α-synuclein-rich Lewy body accumulation. Mitochondrial dysfunction and microRNA (miRNA) dysregulation, particularly mitochondrial miRNAs (mitomiRs), are critical drivers of PD pathogenesis. This study investigated the neuroprotective efficacy of the SGLT2 inhibitor, dapagliflozin, against rotenone-induced neurotoxicity, focusing on the lincRNA-p21/mitomiR-181/PTEN and mitomiR-23b/SIRT1/AMPK signaling axes. Male Wistar rats were randomized into three groups: a control group, a PD model group received rotenone (2 mg/kg every 48 h, s.c.), and a treatment group received rotenone plus dapagliflozin (10 mg/kg/day, p.o.) for 28 days. In the inducted rotenone group lincRNA-p21 sponges mir-181 which leads to the upregulation of PTEN which inhibits the conversion of PIP2 to PIP3 thus downregulating AKT expression and subsequent activation of GSK-3β kinase enzyme which increases α-synuclein accumulation. In addition, the PD-control group showed upregulation of Mitomir-23b with subsequent downregulation of SIRT-1 expression and inactivation of LKB1. Accompanied by inhibition of AMPK phosphorylation which in turn prevents the degradation of accumulated α-synuclein. Dapagliflozin treatment upregulates mir-181 and downregulates mitomir-23b, which restores DJ-1 levels, which in turn activate the antioxidant genes HO-1 and PINK1, and improve mitochondrial function. Dapagliflozin exerts neuroprotection by restoring lincRNA-p21/mitomiR-181/PTEN and mitomiR-23b/SIRT1/AMPK homeostasis, thereby inhibiting α-synuclein proteotoxicity and mitigating oxidative stress and neuroinflammation.
No takes yet. Share an insight, caveat, or question.
Abdelhamid et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: